Latest revision as of 20:56, 21 February 2025

Induced Pluripotent Stem Cell[edit]

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka and his team in 2006, who discovered that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.

History[edit]

The concept of reprogramming adult cells to a pluripotent state was first demonstrated in 2006 by Shinya Yamanaka and Kazutoshi Takahashi. They used mouse fibroblasts and introduced four transcription factors: Oct4, Sox2, Klf4, and c-Myc, collectively known as the Yamanaka factors. This groundbreaking discovery earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012.

Methodology[edit]

The process of creating iPSCs involves the introduction of specific genes into somatic cells. These genes are typically delivered using viral vectors, such as retroviruses or lentiviruses, which integrate into the host cell's genome. Once inside, these genes reprogram the somatic cells to a pluripotent state, similar to that of embryonic stem cells.

Characteristics[edit]

iPSCs share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for regenerative medicine, disease modeling, and drug discovery.

Applications[edit]

iPSCs have numerous applications in the field of medicine and research. They can be used to model diseases, allowing researchers to study the progression and potential treatments for various conditions. Additionally, iPSCs hold promise for regenerative medicine, where they can be used to generate healthy cells to replace damaged or diseased tissues.

Challenges[edit]

Despite their potential, iPSCs face several challenges. One major concern is the risk of tumorigenicity, as the reprogramming process can lead to genetic mutations. Additionally, the use of viral vectors poses a risk of insertional mutagenesis. Researchers are actively working on developing safer and more efficient methods of generating iPSCs.

Future Directions[edit]

The future of iPSC research is promising, with ongoing efforts to improve the safety and efficiency of reprogramming techniques. Advances in gene editing technologies, such as CRISPR-Cas9, offer potential solutions to overcome current challenges. Furthermore, the development of non-integrating delivery methods for reprogramming factors is a key area of focus.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Induced pluripotent stem cells''' ('''iPSCs''') are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was first developed in 2006 by [[Shinya Yamanaka]]'s team at Kyoto University, Japan. They demonstrated that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. This groundbreaking discovery has significant implications for [[regenerative medicine]], [[drug discovery]], and the study of [[disease modeling]].
+= Induced Pluripotent Stem Cell =
-<youtube>
+[[File:Human_induced_pluripotent_stem_cell_colony_(51816035910).jpg|thumb|right|Human induced pluripotent stem cell colony]]
-title='''{{PAGENAME}}'''
-movie_url=http://www.youtube.com/v/ahTjpXPVjQg
-&rel=1
-embed_source_url=http://www.youtube.com/v/ahTjpXPVjQg
-&rel=1
-wrap = yes
-width=750
-height=600
-</youtube>
-==Overview==
+Induced pluripotent stem cells (iPSCs) are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was pioneered by [[Shinya Yamanaka]] and his team in 2006, who discovered that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
-Induced pluripotent stem cells are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells are similar to embryonic stem cells in many respects, iPSCs are not derived from embryos. Instead, they are typically derived from adult somatic cells, such as skin or blood cells. This method of generating pluripotent cells bypasses ethical concerns associated with the use of embryonic stem cells.
-==Generation of iPSCs==
+== History ==
-The original method for creating iPSCs involved the introduction of four specific transcription factors: [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]], collectively known as the Yamanaka Factors. These factors are introduced into the cells using viral vectors, although newer methods have been developed that use non-integrating approaches to avoid potential genomic instability.
-==Applications==
+[[File:Production_of_iPSC_Timeline.png|thumb|left|Timeline of iPSC production]]
-#Regenerative Medicine
-iPSCs hold great promise for regenerative medicine because they can be differentiated into various cell types, including neurons, heart muscle cells, and pancreatic beta cells. This capability makes them a potential source for cell replacement therapies to treat diseases such as [[Parkinson's disease]], [[diabetes]], and [[heart disease]].
-#Drug Discovery and Toxicology
+The concept of reprogramming adult cells to a pluripotent state was first demonstrated in 2006 by Shinya Yamanaka and Kazutoshi Takahashi. They used mouse fibroblasts and introduced four transcription factors: [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]], collectively known as the Yamanaka factors. This groundbreaking discovery earned Yamanaka the [[Nobel Prize in Physiology or Medicine]] in 2012.
-iPSCs can be used to generate disease-specific cell models, which are valuable for drug discovery and toxicology studies. These models can help identify new drug targets and screen for potential drug toxicity, reducing the reliance on animal models.
-#Disease Modeling
+== Methodology ==
-iPSCs can be derived from patients with specific genetic disorders. By differentiating these iPSCs into cell types relevant to the disease, researchers can study the disease mechanisms at the cellular level, potentially leading to new insights and treatments.
+The process of creating iPSCs involves the introduction of specific genes into somatic cells. These genes are typically delivered using viral vectors, such as retroviruses or lentiviruses, which integrate into the host cell's genome. Once inside, these genes reprogram the somatic cells to a pluripotent state, similar to that of embryonic stem cells.
-==Ethical Considerations==
+== Characteristics ==
-The development of iPSC technology has addressed some of the ethical concerns associated with embryonic stem cell research, as iPSCs can be generated without the need for embryos. However, ethical considerations still exist, particularly regarding the potential for genetic modifications and the long-term effects of iPSC-derived therapies.
-==Challenges and Limitations==
+iPSCs share many characteristics with [[embryonic stem cells]], including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for regenerative medicine, disease modeling, and drug discovery.
-Despite their potential, the use of iPSCs is not without challenges. Issues such as the efficiency of cell reprogramming, the stability of the reprogrammed cells, and the risk of tumorigenesis due to the use of oncogenes like c-Myc in the reprogramming process are areas of ongoing research.
-==Future Directions==
+== Applications ==
-Research on iPSCs is rapidly advancing, with efforts focused on improving the efficiency and safety of iPSC generation, understanding the mechanisms underlying pluripotency and differentiation, and developing new applications for these cells in medicine and research.
-[[Category:Cell biology]]
+[[File:Three_germ_line_cells_differentiated_from_iPSCs.png|thumb|left|Three germ line cells differentiated from iPSCs]]
+iPSCs have numerous applications in the field of medicine and research. They can be used to model diseases, allowing researchers to study the progression and potential treatments for various conditions. Additionally, iPSCs hold promise for regenerative medicine, where they can be used to generate healthy cells to replace damaged or diseased tissues.
+== Challenges ==
+Despite their potential, iPSCs face several challenges. One major concern is the risk of tumorigenicity, as the reprogramming process can lead to genetic mutations. Additionally, the use of viral vectors poses a risk of insertional mutagenesis. Researchers are actively working on developing safer and more efficient methods of generating iPSCs.
+== Future Directions ==
+[[File:Induction_of_iPS_cells.svg|thumb|right|Induction of iPS cells]]
+The future of iPSC research is promising, with ongoing efforts to improve the safety and efficiency of reprogramming techniques. Advances in gene editing technologies, such as [[CRISPR-Cas9]], offer potential solutions to overcome current challenges. Furthermore, the development of non-integrating delivery methods for reprogramming factors is a key area of focus.
+== Related Pages ==
+* [[Pluripotent stem cell]]
+* [[Embryonic stem cell]]
+* [[Shinya Yamanaka]]
+* [[Regenerative medicine]]
+[[Category:Stem cells]]
 [[Category:Regenerative medicine]]
-[[Category:Stem cells]]
-{{Medicine-stub}}
-<gallery>
-File:Human_induced_pluripotent_stem_cell_colony_(51816035910).jpg|Human induced pluripotent stem cell colony
-File:Human_iPS_cells_colonies.png|Human iPS cells colonies
-File:Dedifferentiation_Methods_(2010)_-_Bischoff,_Steven_R.tif|Dedifferentiation Methods (2010) - Bischoff, Steven R.
-File:Induction_of_iPS_cells.svg|Induction of iPS cells
-File:Production_of_iPSC_Timeline.png|Production of iPSC Timeline
-File:Three_germ_line_cells_differentiated_from_iPSCs.png|Three germ line cells differentiated from iPSCs
-</gallery>

Induced pluripotent stem cell: Difference between revisions